Centessa Pharmaceuticals(US:CNTA)2022-09-15 17:29Financial Status and Pipeline Overview - Centessa Pharmaceuticals had $484.2 million in cash and cash equivalents as of June 30, 2022, providing a cash runway into 2026 to enable clinical proof of concept readouts across the portfolio[6, 9, 52] - The company is developing multiple potential blockbuster assets with clinical readouts anticipated over the next two years[6, 52] Lead Asset Programs - SerpinPC (Hemophilia B): - The estimated market size for Hemophilia B is over $2 billion[8, 13] - Phase 2a open label extension (OLE) data is expected in Q4 2022, and registrational studies for hemophilia B are expected to start in the second half of 2022[9, 16] - In a Phase 2a study, the highest dose cohort (1.2 mg/kg) showed a median ABR reduction of 88% for all bleeds (reduced from 36.0 to 4.4) and a 94% reduction for spontaneous joint bleeds (reduced from 21.1 to 2.2)[19] - LB101 (Solid Tumors): - The estimated market size for solid tumors is $10 billion[8] - An IND (Investigational New Drug) submission is planned for late 2022[9, 30] - In preclinical studies, LB101 at 17 mg/kg resulted in tumor regression in 14 out of 16 mice in a difficult-to-treat mouse model[34] - MGX292 (Pulmonary Arterial Hypertension - PAH): - The estimated global market size for PAH is over $6 billion[8, 39] - Preclinical data demonstrated dose-dependent reversal of established lung vascular pathology in a Sugen-hypoxia rat model[42] - OX2R Agonists (Narcolepsy Type 1 - NT1): - The estimated market size for narcolepsy is over $2 billion[8, 47] - Approximately 50% of narcolepsy patients have NT1[47]